For the twelve months ended Jun 30, 2026, Kyntra Bio Inc. reported $4.62M of revenue and $183.19M of net income.
KYNB revenue was -$1.47M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $1.35M a year earlier. For the full fiscal 2025 it was $6.44M, down 78.3% from fiscal 2024. Compound annual growth was -48.4% over 5 years and -28.4% over 10 years. It rose in 4 of the last 10 fiscal years.
KYNB net income was $11.97M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$7.60M a year earlier. For the full fiscal 2025 it was $183.45M, compared with -$47.58M in fiscal 2024. Fiscal 2025 is the highest of the 13 fiscal years on file.
KYNB diluted EPS was $2.96 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.88 a year earlier. For the full fiscal 2025 it was $45.37, compared with -$11.89 in fiscal 2024.
KYNB free cash flow was -$3.99M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $12.67M a year earlier. For the full fiscal 2025 it was -$4.81M, compared with -$138.26M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.44M | $29.62M | $46.80M | $140.73M | $235.31M | $176.32M | $256.58M | $212.96M | $131.00M | $183.19M |
| Cost of revenue | $556.0K | $15.56M | $3.96M | $20.28M | $12.87M | $8.87M | $1.15M | - | - | - |
| Gross profit | $5.88M | $14.06M | $42.84M | $120.45M | $222.44M | $167.45M | $255.43M | - | - | - |
| Research and development | $23.52M | $95.69M | $266.47M | $296.79M | $387.04M | $252.92M | $209.26M | $235.84M | $196.52M | $187.21M |
| Selling, general and admin | $27.71M | $49.33M | $86.48M | $124.69M | $123.92M | $106.41M | $135.48M | $63.81M | $51.76M | $46.02M |
| Operating income | -$45.90M | -$150.42M | -$322.72M | -$301.02M | -$288.53M | -$191.88M | -$89.31M | -$86.69M | -$117.28M | -$50.04M |
| Interest expense | $8.76M | $8.25M | $8.10M | $1.44M | $1.07M | $2.40M | $2.88M | $10.99M | $9.71M | $10.72M |
| Pre-tax income | -$58.29M | -$153.37M | -$323.22M | -$294.87M | -$290.68M | -$188.73M | -$76.64M | -$86.12M | -$120.55M | -$58.14M |
| Income tax | -$90.0K | -$269.0K | -$252.0K | $358.0K | $347.0K | $360.0K | $328.0K | $304.0K | $321.0K | -$71.0K |
| Net income | $183.45M | -$47.58M | -$284.23M | -$293.65M | -$290.02M | -$189.29M | -$76.97M | -$86.42M | -$120.88M | -$58.07M |
| EPS, basic | $45.37 | -$11.89 | -$73.00 | -$78.50 | -$78.50 | -$52.75 | -$22.25 | -$25.75 | -$41.50 | -$23.25 |
| EPS, diluted | $45.37 | -$11.89 | -$73.00 | -$78.50 | -$78.50 | -$52.75 | -$22.25 | -$25.75 | -$41.50 | -$23.25 |
| Diluted shares | 4.0M | 4.0M | 3.9M | 3.7M | 3.7M | 3.6M | 3.5M | 3.4M | 2.9M | 2.5M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $47.87M | $50.48M | $81.55M | $155.70M | $171.22M | $678.39M | $126.27M | $89.26M | $673.66M | $173.78M |
| Short-term investments | $41.11M | $0 | $121.90M | $266.31M | $233.97M | $8.14M | $407.49M | $532.14M | $62.06M | - |
| Receivables | $216.0K | $481.0K | $5.12M | $16.30M | $17.40M | $41.88M | $28.45M | $63.68M | $8.45M | $10.45M |
| Inventory | $3.74M | $3.15M | $17.17M | $40.44M | $31.02M | $16.53M | $6.89M | $0 | - | - |
| Current assets | $99.07M | $196.51M | $331.56M | $492.83M | $474.06M | $755.11M | $702.49M | $690.01M | $748.97M | $266.52M |
| Total assets | $119.59M | $214.53M | $423.53M | $610.09M | $773.82M | $826.84M | $857.40M | $880.60M | $898.65M | $469.55M |
| Current liabilities | $29.24M | $133.31M | $217.67M | $273.56M | $225.50M | $163.19M | $102.75M | $89.03M | $85.96M | $65.13M |
| Total liabilities | $115.12M | $398.16M | $585.73M | $611.57M | $544.71M | $385.39M | $321.99M | $352.13M | $350.91M | $294.44M |
| Shareholders' equity | -$30.04M | -$205.12M | -$183.68M | -$1.48M | $229.11M | $441.45M | $535.41M | $528.47M | $547.74M | $135.07M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.77M | -$138.00M | -$315.02M | -$145.93M | -$82.23M | $81.60M | -$78.70M | -$76.14M | -$66.51M | $7.11M |
| Capital expenditures | $38.0K | $266.0K | $2.52M | $3.74M | $5.19M | $3.99M | $5.76M | $8.02M | $8.50M | $1.25M |
| Free cash flow | -$4.81M | -$138.26M | -$317.54M | -$149.67M | -$87.42M | $77.61M | -$84.47M | -$84.16M | -$75.01M | $5.86M |
| Investing cash flow | $35.42M | $125.99M | $153.66M | $89.12M | -$426.97M | $452.49M | $120.02M | -$522.12M | $69.87M | $6.62M |
| Financing cash flow | -$86.03M | -$255.0K | $122.75M | $46.78M | -$563.0K | $13.34M | -$4.30M | $13.88M | $496.47M | $6.74M |
| Stock-based compensation | $6.58M | $25.21M | $50.77M | $65.60M | $71.16M | $72.72M | $66.27M | $52.14M | $37.54M | $32.13M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -78.3% | -36.7% | -66.7% | -40.2% | 33.5% | -31.3% | 20.5% | 62.6% | -28.5% | 1.3% |
| Gross margin | 91.4% | 47.5% | 91.5% | 85.6% | 94.5% | 95.0% | 99.6% | - | - | - |
| Operating margin | -712.7% | -507.8% | -689.5% | -213.9% | -122.6% | -108.8% | -34.8% | -40.7% | -89.5% | -27.3% |
| Net margin | 2848.6% | -160.6% | -607.3% | -208.7% | -123.3% | -107.4% | -30.0% | -40.6% | -92.3% | -31.7% |
| Free cash flow margin | -74.7% | -466.8% | -678.5% | -106.4% | -37.2% | 44.0% | -32.9% | -39.5% | -57.3% | 3.2% |
| Return on equity | - | - | - | - | -126.6% | -42.9% | -14.4% | -16.4% | -22.1% | -43.0% |
| Return on assets | 153.4% | -22.2% | -67.1% | -48.1% | -37.5% | -22.9% | -9.0% | -9.8% | -13.5% | -12.4% |
| Current ratio | 3.39 | 1.47 | 1.52 | 1.80 | 2.10 | 4.63 | 6.84 | 7.75 | 8.71 | 4.09 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$1.47M | $3.74M | $1.28M | $1.08M | $1.35M | $2.74M | $3.13M | $123.0K | $998.0K | $25.36M | - | $40.13M |
| Cost of revenue | $2.0K | $4.11M | $278.0K | -$58.0K | $85.0K | $252.0K | -$5.85M | -$75.0K | $140.0K | $21.34M | -$9.48M | $4.24M |
| Gross profit | -$1.48M | -$368.0K | $999.0K | $1.13M | $1.26M | $2.49M | $8.98M | $198.0K | $858.0K | $4.02M | - | $35.89M |
| Research and development | $6.82M | $7.57M | $7.27M | $1.21M | $5.87M | $9.18M | $6.87M | $19.97M | $32.36M | $36.49M | $35.31M | $61.19M |
| Selling, general and admin | $9.27M | $5.86M | $7.25M | $5.29M | $7.06M | $8.11M | $8.35M | $9.36M | $14.91M | $16.71M | -$4.55M | $25.57M |
| Operating income | -$17.57M | -$13.82M | -$13.51M | -$5.41M | -$12.05M | -$14.92M | -$7.13M | -$47.69M | -$46.41M | -$49.18M | -$95.10M | -$63.48M |
| Interest expense | $2.37M | $2.43M | $2.41M | $2.08M | $2.01M | $2.26M | $2.22M | $2.07M | $1.87M | $2.09M | -$2.37M | $5.02M |
| Pre-tax income | $11.97M | -$15.13M | -$14.61M | -$13.15M | -$13.78M | -$16.76M | -$8.66M | -$48.29M | -$47.38M | -$49.04M | -$93.12M | -$64.21M |
| Income tax | -$1.0K | $0 | $0 | $0 | -$92.0K | $2.0K | $2.0K | $3.0K | -$281.0K | $7.0K | -$175.0K | $84.0K |
| Net income | $11.97M | -$15.20M | -$14.22M | $200.64M | -$7.60M | $4.64M | $17.98M | -$17.08M | -$15.54M | -$32.93M | -$56.23M | -$63.62M |
| EPS, basic | $2.96 | -$3.76 | -$3.51 | $49.61 | -$1.88 | $1.15 | $4.50 | -$4.25 | -$3.89 | -$8.25 | -$14.00 | -$16.25 |
| EPS, diluted | $2.96 | -$3.76 | -$3.51 | $49.61 | -$1.88 | $1.15 | $4.50 | -$4.25 | -$3.89 | -$8.25 | -$14.00 | -$16.25 |
| Diluted shares | 4.0M | 4.0M | - | 4.0M | 4.0M | 4.0M | - | 4.0M | 4.0M | 4.0M | - | 3.9M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $50.64M | $37.00M | $47.87M | $117.97M | $23.37M | $33.61M | $50.48M | $131.00M | $140.71M | $105.73M | $81.55M | $120.91M |
| Short-term investments | $40.67M | $50.24M | $41.11M | - | - | - | $0 | $0 | $0 | $71.86M | $121.90M | $130.43M |
| Receivables | $347.0K | $5.04M | $216.0K | $121.0K | $136.0K | $147.0K | $481.0K | $29.03M | $6.41M | $37.08M | $5.12M | $31.69M |
| Inventory | $3.38M | $3.38M | $3.74M | $3.86M | $3.86M | $3.15M | $3.15M | $23.94M | $25.40M | $27.34M | $17.17M | $40.70M |
| Current assets | $96.83M | $101.36M | $99.07M | $133.42M | $162.32M | $148.53M | $196.51M | $244.53M | $209.46M | $278.17M | $331.56M | $364.11M |
| Total assets | $101.08M | $109.63M | $119.59M | $137.01M | $178.06M | $165.21M | $214.53M | $264.42M | $293.20M | $365.87M | $423.53M | $460.43M |
| Current liabilities | $36.04M | $28.11M | $29.24M | $35.97M | $155.90M | $73.39M | $133.31M | $190.53M | $148.59M | $196.73M | $217.67M | $209.41M |
| Total liabilities | $109.22M | $118.92M | $115.12M | $119.53M | $359.08M | $340.14M | $398.16M | $466.12M | $483.58M | $552.02M | $585.73M | $575.63M |
| Shareholders' equity | -$30.14M | -$30.77M | -$30.04M | -$17.03M | -$202.51M | -$196.41M | -$205.12M | -$223.18M | -$211.85M | -$207.63M | -$183.68M | -$136.68M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.99M | -$13.89M | -$18.33M | -$1.85M | $12.68M | $2.72M | -$30.47M | -$8.38M | -$39.87M | -$59.29M | -$18.32M | -$84.54M |
| Capital expenditures | $0 | $0 | $0 | $9.0K | $13.0K | $16.0K | $141.0K | $82.0K | $14.0K | $29.0K | $251.0K | $684.0K |
| Free cash flow | -$3.99M | -$13.89M | -$18.33M | -$1.86M | $12.67M | $2.70M | -$30.61M | -$8.46M | -$39.88M | -$59.32M | -$18.57M | -$85.22M |
| Investing cash flow | $17.67M | $3.02M | -$51.71M | $87.16M | -$13.0K | -$16.0K | $1.72M | $755.0K | $72.24M | $51.28M | $10.24M | $54.22M |
| Financing cash flow | -$5.0K | -$7.0K | -$14.0K | -$85.92M | -$9.0K | -$88.0K | $5.0K | -$127.0K | $32.0K | -$165.0K | -$246.0K | -$22.0K |
| Stock-based compensation | $984.0K | $1.15M | $1.19M | $662.0K | $1.87M | $2.85M | $178.0K | $7.69M | $8.59M | $8.76M | $9.30M | $9.48M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -209.3% | 36.5% | -59.3% | 774.8% | 35.1% | -89.2% | - | -99.7% | -97.7% | -29.9% | - | 155.1% |
| Gross margin | - | -9.8% | 78.2% | 105.4% | 93.7% | 90.8% | 286.5% | 161.0% | 86.0% | 15.9% | - | 89.4% |
| Operating margin | - | -369.7% | -1058.1% | -502.9% | -894.1% | -544.7% | -227.5% | -38774.0% | -4650.1% | -193.9% | - | -158.2% |
| Net margin | - | -406.6% | -1113.5% | 18646.5% | -564.0% | 169.4% | 573.6% | -13889.4% | -1557.5% | -129.8% | - | -158.5% |
| Free cash flow margin | - | -371.5% | -1435.2% | -172.5% | 939.8% | 98.7% | -976.3% | -6876.4% | -3996.3% | -233.9% | - | -212.3% |
| Current ratio | 2.69 | 3.61 | 3.39 | 3.71 | 1.04 | 2.02 | 1.47 | 1.28 | 1.41 | 1.41 | 1.52 | 1.74 |
Source: XBRL data Kyntra Bio Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Aug 11, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KYNB | $4.62M | -37.1% | $183.19M | 3967.8% | $15.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |